Table 3.

AEs of CTCAE grade 3 or higher (safety population)

System organ class and preferred term	Cohort 1: 0.01 mg/kg (n = 3)	Cohort 2: 0.04 mg/kg (n = 3)	Cohort 3: 0.15 mg/kg (n = 3)	Cohort 4: 0.5 mg/kg (n = 6)	Cohort 5: 1.5 mg/kg (n = 3)	Cohort 6: 4.5 mg/kg (n = 3)	Cohort 7: 7 mg/kg (n = 3)	Cohort 8: 2 × 4.5 mg/kg (n = 4)	Overall (n = 28)
Any AE of CTCAE grade ≥3	0	0	0	1 (16.7)	3 (100.0)	1 (33.3)	2 (66.7)	1 (25.0)	8 (28.6)
Blood and lymphatic disorders
Anemia	0	0	0	1 (16.7)	0	1 (33.3)	0	0	2 (7.1)
Hemolytic anemia	0	0	0	1 (16.7)	0	0	0	0	1 (3.6)
Thrombocytopenia	0	0	0	1 (16.7)	0	0	0	0	1 (3.6)
General disorders
Multiorgan failure	0	0	0	1 (16.7)	0	0	0	0	1 (3.6)
Pyrexia	0	0	0	0	1 (33.3)	0	0	0	1 (3.6)
Thrombosis in device	0	0	0	0	1 (33.3)	0	0	0	1 (3.6)
Infections and infestations
Bronchitis	0	0	0	0	1 (33.3)	0	0	0	1 (3.6)
Pneumonia	0	0	0	1 (16.7)	1 (33.3)	0	1 (33.3)	1 (25.0)	4 (14.3)
Staphylococcal infection	0	0	0	0	0	0	1 (33.3)	0	1 (3.6)
Investigations
Bilirubin increased	0	0	0	1 (16.7)	0	0	0	0	1 (3.6)
Metabolism and nutrition
Hypoalbuminemia	0	0	0	1 (16.7)	0	0	0	0	1 (3.6)
Neoplasms
T-cell lymphoma	0	0	0	0	1 (33.3)	0	0	0	1 (3.6)

Data are presented as n (%) of AEs.